<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Porfimer: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Porfimer: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Porfimer: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12193" href="/d/html/12193.html" rel="external">see "Porfimer: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F211474"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Photofrin</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F211499"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Miscellaneous</li></ul></div>
<div class="block doa drugH1Div" id="F211478"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0c0b8a1e-ecd9-4bed-b090-bfc96d532167">Barrett esophagus dysplasia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Barrett esophagus dysplasia (photodynamic therapy):</b>
<b>IV:</b> 2 mg/kg, followed by endoscopic exposure to the appropriate laser light; repeat courses must be separated by at least 90 days (delay subsequent treatment for insufficient healing) for a maximum of 3 courses.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3dee4c43-e018-4d42-a254-79273026b31d">Cholangiocarcinoma, unresectable</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cholangiocarcinoma, unresectable (photodynamic therapy) (off-label use): IV:</b> 2 mg/kg, followed 48 hours later by light activation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14598251']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14598251'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="64be14b8-14c1-47a5-917e-cd456604f056">Endobronchial non-small cell lung cancer</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endobronchial non-small cell lung cancer (photodynamic therapy):</b>
<b>IV:</b> 2 mg/kg, followed by endoscopic exposure to the appropriate laser light and debridement; repeat courses must be separated by at least 30 days (delay subsequent treatment for insufficient healing) for a maximum of 3 courses.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e50dc227-3f50-48ae-aba5-898bd2fb9c33">Esophageal cancer</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Esophageal cancer (photodynamic therapy):</b>
<b>IV:</b> 2 mg/kg, followed by endoscopic exposure to the appropriate laser light and debridement; repeat courses must be separated by at least 30 days (delay subsequent treatment for insufficient healing) for a maximum of 3 courses.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990358"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); use caution as porfimer elimination (and photosensitivity) may be prolonged.</p></div>
<div class="block doha drugH1Div" id="F50987731"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); use caution as porfimer elimination (and photosensitivity) may be prolonged.</p></div>
<div class="block doe drugH1Div" id="F211479"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F211446"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain (8% to 22%), edema (5% to 18%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin photosensitivity (19% to 69%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Esophageal stenosis (6% to 38%), nausea (24%), constipation (5% to 24%), abdominal pain (20%), vomiting (17%), dysphagia (10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (esophageal cancer: 32%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Pain (5% to 22%), insomnia (5% to 14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (3% to 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pleural effusion (5% to 32%), dyspnea (7% to 30%), bronchial obstruction (≤21%), bronchial plugs (≤21%), pneumonia (12% to 18%), hemoptysis (16%), cough (7% to 15%), bronchoconstriction (bronchostenosis: 11%), pharyngitis (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (16% to 31%), serous drainage (22%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Atrial fibrillation (10%), hypotension (7%), peripheral edema (5% to 7%), cardiac failure (≤7%), hypertension (6%), tachycardia (6%), substernal pain (5%), acute myocardial infarction (&lt;5%), angina pectoris (&lt;5%), bradycardia (&lt;5%), pulmonary embolism (&lt;5%), sick sinus syndrome (&lt;5%), supraventricular tachycardia (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Weight loss (9%), dehydration (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia (8%), disease of esophagus (esophageal edema: 8%), hematemesis (8%), tracheoesophageal fistula (6%), dyspepsia (2% to 6%), diarrhea (5%), eructation (5%), esophagitis (5%), melena (5%), esophageal perforation (&lt;5%), gastric ulcer (&lt;5%), intestinal obstruction (&lt;5%), peritonitis (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Tumor hemorrhage (8%), pulmonary hemorrhage (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Jaundice (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Candidiasis (9%), abscess (lung: &lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Confusion (8%), anxiety (6% to 7%), voice disorder (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Asthenia (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Diplopia (&lt;5%), eye pain (&lt;5%), photophobia (&lt;5%), visual disturbance (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis (≤10%), respiratory insufficiency (6% to 10%), bronchospasm (&lt;5%), laryngeal edema (&lt;5%), pneumonitis (&lt;5%), productive cough (8%), pulmonary edema (&lt;5%), respiratory failure (&lt;5%), stridor (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Ulcer (bronchial: 9%), postoperative complication (5%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Cataract, cerebrovascular accident, cutaneous nodule, fluid volume disorder, fragile skin, gastrointestinal necrosis, gastrointestinal perforation, hemorrhage, hypertrichosis, infusion related reaction (including dizziness and urticaria), local tissue necrosis (esophageal), pseudoporphyria, sepsis, skin discoloration, thromboembolism, wrinkling of skin</p></div>
<div class="block coi drugH1Div" id="F211459"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Porphyria; photodynamic therapy (PDT) is contraindicated in patients with existing tracheoesophageal or bronchoesophageal fistula, tumors eroding into a major blood vessel, emergency treatment of severe acute respiratory distress when caused by an obstructing endobronchial lesion, esophageal or gastric varices, esophageal ulcers &gt;1 cm in diameter.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<i>Canadian labeling: </i> Additional contraindications (not in the US labeling): Hypersensitivity to porphyrins; PDT is contraindicated in patients with papillary bladder cancer who have received prior total bladder radiation or whose functional bladder capacity is &lt;200 mL and in patients with coexisting bladder tumors of stage greater than stage 1 (T1) who have invasive cancer.</p></div>
<div class="block war drugH1Div" id="F211443"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Airway obstruction: Treatment-induced inflammation may obstruct airway. Use with caution in patients with endobronchial tumors, especially if in areas where main airway may be obstructed (long or surrounding tumors). Necrotic debris or mucositis may also cause airway obstruction. Monitor closely between laser therapy and debridement for respiratory distress; may require urgent bronchoscopy to remove secretions or debris.</p>
<p style="text-indent:-2em;margin-left:4em;">• Chest pain: Inflammatory responses within the treatment area may result in substernal chest pain.</p>
<p style="text-indent:-2em;margin-left:4em;">• Esophageal strictures: Esophageal strictures may occur, usually within 6 months of treatment. May require multiple dilations to resolve. The risk is increased with nodule pretreatment or with re-treatment of the same area.</p>
<p style="text-indent:-2em;margin-left:4em;">• Extravasation: Avoid extravasation. If extravasation occurs, protect affected area from light; use of antidotes is of unknown benefit.</p>
<p style="text-indent:-2em;margin-left:4em;">• Gastroesophageal fistula/perforation: Serious and potentially fatal gastrointestinal and esophageal necrosis and perforation may occur following treatment. Due to the high risk for fistula, do not use in patients with esophageal tumors eroding into the trachea or bronchial tree/wall. Use is contraindicated in patients with existing tracheoesophageal or bronchoesophageal fistula.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hemorrhage: Patients with esophageal varices or tumors eroding into pulmonary blood vessels are at increased risk for hemorrhage, including fatal massive pulmonary hemoptysis (FMH). Do not administer light directly to an area with esophageal varices due to the potential for hemorrhage. Other risk factors for FMH include large, centrally located tumors, cavitating tumors, or extensive tumor extrinsic to the bronchus.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular photosensitivity: Ocular discomfort has been reported with sun or bright light exposure (or car headlights). For at least 30 days (and until ocular sensitivity resolves), when outdoors, patients should wear dark sunglasses that have an average white light transmittance of &lt;4%.</p>
<p style="text-indent:-2em;margin-left:4em;">• Photosensitivity: Photosensitivity reactions are common in patients who are exposed to direct sunlight or bright indoor light (eg fluorescent lights, unshaded light bulbs, examination/operating lights). Conventional UV sunscreens are <b>not</b> protective against photosensitivity reactions caused by visible light. Photosensitivity may last 30 to 90 days or more. Encourage exposure to ambient indoor light (aids in gradually inactivating residual porfimer). Patients should be educated to test for residual photosensitivity before resuming exposure to sunlight. Re-exposure to general sunlight should be gradual (expose small area of skin [not the face] for 10 minutes), if no photosensitivity (eg, edema, erythema, blistering) occurs after 24 hours, may gradually resume normal outdoor activities; if photosensitivity occurs then wait 2 weeks and retest.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thromboembolism: Thromboembolic events may occur, generally in patients with additional risk factors for thromboembolism (eg, advanced cancer, prolonged immobilization, cardiovascular disease, following major surgery).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Barrett esophagus: In patients with Barrett esophagus, conduct rigorous surveillance (endoscopic biopsy every 3 months until 4 consecutive negative results for high-grade dysplasia followed by further follow-up per physician judgment). The long-term effects of photodynamic therapy in patients with Barrett esophagus are not known. Esophageal strictures are common adverse events associated with photodynamic therapy of Barrett esophagus; esophageal dilation may be required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Esophageal/gastric varices: Not suited for treatment of patients with esophageal or gastric varices (due to the high risk for hemorrhage).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Elimination may be prolonged in hepatic impairment; toxicities may be increased. Photosensitivity may persist beyond 90 days in patients with mild to severe hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Elimination may be prolonged in renal impairment; toxicities may be increased. Photosensitivity may persist beyond 90 days in patients with severe renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Photosensitizing drugs: Concurrent use with other photosensitizing agents may increase the risk for photosensitivity reactions.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Radiation therapy recipients: Allow 2 to 4 weeks to elapse after phototherapy prior to initiating radiation therapy; 4 weeks should elapse after radiation therapy prior to initiating phototherapy.</p></div>
<div class="block foc drugH1Div" id="F211453"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous, as sodium [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Photofrin: 75 mg (1 ea)</p></div>
<div class="block geq drugH1Div" id="F211439"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16323709"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Photofrin Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">75 mg (per each): $27,166.80</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F211456"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">IV: Administer slow IV injection over 3 to 5 minutes. Avoid extravasation (if extravasation occurs, protect area from light and sunlight).</p>
<p style="text-indent:0em;margin-top:2em;">Due to the potential for photosensitivity reactions, wear rubber gloves and eye protection and avoid skin and eye contact during administration; if overexposure occurs, protect from bright light. Spills should be wiped with a damp cloth and contaminated material should be disposed of properly.</p></div>
<div class="block use drugH1Div" id="F211454"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Barrett esophagus dysplasia (photodynamic therapy):</b> Ablation of high-grade dysplasia in Barrett esophagus (in patients who do not undergo esophagectomy)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Endobronchial cancer (photodynamic therapy):</b> Treatment of microinvasive endobronchial non-small cell lung cancer (NSCLC) in patients for whom surgery and radiation therapy are not indicated; reduction of obstruction and symptom palliation in patients with obstructing (partial or complete) endobronchial NSCLC</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Esophageal cancer (photodynamic therapy):</b> Palliation of completely obstructing esophageal cancer, or partially obstructing esophageal cancer in patients who cannot be treated satisfactorily with Nd:YAG laser therapy.</p></div>
<div class="block off-label drugH1Div" id="F54762379"><span class="drugH1">Use: Off-Label: Adult</span><p>Cholangiocarcinoma (unresectable)</p></div>
<div class="block mst drugH1Div" id="F55786586"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299910"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F211448"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxsalen (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Methoxsalen (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Photosensitizing Agents: May enhance the photosensitizing effect of Porfimer.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F54126244"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Evaluate pregnancy status prior to use in females of reproductive potential. Females of reproductive potential should use effective contraception during treatment and for 5 months after the last porfimer dose. Males with female partners of reproductive potential should use condoms during treatment and for 5 months after the last porfimer dose.</p></div>
<div class="block pri drugH1Div" id="F211461"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on the mechanism of action and data from animal reproduction studies, in utero exposure to porfimer may cause fetal harm.</p></div>
<div class="block brc drugH1Div" id="F13185708"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if porfimer is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer during treatment and for 5 months after the last porfimer dose.</p></div>
<div class="block mop drugH1Div" id="F27259307"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Evaluate pregnancy status prior to use in females of reproductive potential. Monitor injection site during infusion (for extravasation); monitor in between laser and debridement for evidence of respiratory distress in patients with endobronchial tumors; monitor for signs/symptoms of photosensitivity, hemorrhage, thromboembolic events, gastroesophageal fistulas/perforation, esophageal strictures.</p></div>
<div class="block pha drugH1Div" id="F211442"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Porfimer's cytotoxic activity is dependent on light and oxygen. Following administration, the drug is selectively retained in neoplastic tissues. Exposure of the drug to laser light at wavelengths &gt;630 nm results in the production of oxygen free-radicals. Release of thromboxane A<sub>2</sub>, leading to vascular occlusion and ischemic necrosis, may also occur.</p></div>
<div class="block phk drugH1Div" id="F211458"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>dss</sub>: 0.49 ± 0.28 L/kg (Pereira 2010).</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding, plasma: ~90%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: First dose: ~17 days; Second dose: ~30 days.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F211462"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Photofrin</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Photofrin</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Photofrin</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Photobarr | Photofrin</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Photofrin</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Photofrin</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Photofrin</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Photofrin</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Photofrin</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Photofrin</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-14598251">
<a name="14598251"></a>Ortner ME, Caca K, Berr F, et al. Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. <i>Gastroenterology</i>. 2003;125(5):1355-1363. doi:10.1016/j.gastro.2003.07.015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/porfimer-drug-information/abstract-text/14598251/pubmed" id="14598251" target="_blank">14598251</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17643436">
<a name="17643436"></a>Overholt BF, Wang KK, Burdick JS, et al, “Five-Year Efficacy and Safety of Photodynamic Therapy With Photofrin in Barrett's High-Grade Dysplasia,” <i>Gastrointest Endosc</i>, 2007, 66(3):460-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/porfimer-drug-information/abstract-text/17643436/pubmed" id="17643436" target="_blank">17643436</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20629974">
<a name="20629974"></a>Pereira SP, Ayaru L, Ackroyd R, et al, “The Pharmacokinetics and Safety of Porfimer After Repeated Administration 30-45 Days Apart to Patients Undergoing Photodynamic Therapy,” <i>Aliment Pharmacol Ther</i>, 2010, 32(6):821-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/porfimer-drug-information/abstract-text/20629974/pubmed" id="20629974" target="_blank">20629974</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Photofrin (porfimer) [prescribing information]. Bannockburn, IL: Pinnacle Biologics Inc; November 2021.</div>
</li>
<li>
<div class="reference">
                  Photofrin (porfimer) [Canadian product monograph]. St. Michael, Barbados: Concordia Laboratories Inc; October 2014.</div>
</li></ol></div><div id="topicVersionRevision">Topic 9791 Version 143.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
